Sareum Holdings PLC Research Update - SDC-1802 anti-cancer poster (5350R)
30 Ottobre 2019 - 8:00AM
UK Regulatory
TIDMSAR
RNS Number : 5350R
Sareum Holdings PLC
30 October 2019
(AIM: SAR)
30 October 2019
SAREUM HOLDINGS PLC
("Sareum" or the "Company")
Sareum presents data highlighting the anti-tumour activity of
TYK2/JAK1 Inhibitor SDC-1802 in multiple cancer disease models via
a novel immunotherapeutic mechanism of action
Poster presented at AACR-NCI-EORTC cancer conference
Sareum Holdings plc, the specialist small molecule drug
development business, announces that its CEO, Dr Tim Mitchell,
presented data yesterday demonstrating how SDC-1802 (formerly known
as SAR-20351), a novel selective TYK2/JAK1 inhibitor discovered by
Sareum, significantly reduces tumour growth in disease models of
cancers of the pancreas, colon, skin and kidney, plus B-cell
lymphoma. The studies showed that SDC-1802 induces this anti-cancer
activity through a novel immunotherapeutic mechanism of action that
stimulates the local immune system to attack cancer cells.
These positive results were seen when SDC-1802/SAR-20351 was
dosed orally, both as a monotherapy and in combination with
standard-of-care therapies. These data provide support for
TYK2/JAK1 inhibition as a potentially powerful new immunotherapy
approach and for the further development of SDC-1802 as a novel
cancer therapeutic.
The data were presented in a poster at the American Association
for Cancer Research (AACR) National Cancer Institute (NCI) European
Organisation for Research and Treatment of Cancer (EORTC)
International Conference (26-30 October 2019 in Boston, USA). The
poster entitled "Immunotherapeutic effects of the TYK2 inhibitor
SAR-20351 in syngeneic tumour models" (Abstract C086) has been
published on the Company's website at
http://www.sareum.com/news/patents-and-publications.
Sareum's CEO, Dr Tim Mitchell, commented: "We were pleased to
present these data highlighting the anti-tumour effects of our oral
TYK2/JAK1 inhibitor SDC-1802 and its immunotherapeutic mechanism
yesterday at AACR-NCI-EORTC. The conference is an important
international cancer congress showcasing innovative research from
academic and pharmaceutical organisations from around the world.
There was a good level of interest directed at novel immunotherapy
mechanisms such as TYK2/JAK1 inhibition and we look forward to
further discussions with interested parties."
For further information, please contact:
Sareum Holdings plc
Tim Mitchell 01223 497 700
Strand Hanson Limited (Nominated Adviser)
James Dance / Richard Tulloch 020 7409 3494
Hybridan LLP (Nominated Broker)
Claire Noyce / John Beresford-Peirse 020 3764 2341
Citigate Dewe Rogerson (Media enquiries)
Shabnam Bashir/ Mark Swallow/ David
Dible 020 7638 9571
Notes for editors:
Sareum is a specialist drug development company delivering
targeted small molecule therapeutics to improve the treatment of
cancer and autoimmune disease. The Company aims to generate value
through licensing its candidates to international pharmaceutical
and biotechnology companies at the preclinical or early clinical
trials stage.
Sareum is advancing internal programmes focused on distinct dual
tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through
preclinical development as therapies for autoimmune diseases
(SDC-1801) and cancers (SDC-1802). The Company is targeting first
human clinical trials in each indication in 2020.
Sareum also has an economic interest in SRA737, a clinical-stage
oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets
cancer cell replication and DNA damage repair mechanisms.
Preliminary data suggest SRA737 may have broad application in
combination with other oncology and immune-oncology drugs in
genetically defined patients. SRA737 was discovered and initially
developed by scientists at The Institute of Cancer Research in
collaboration with Sareum, and with funding from Cancer Research
UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra
Oncology, in a $328.5m plus royalties licence deal, with Sareum
eligible to receive 27.5% of all payments to CPF under the
agreement.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at
www.sareum.co.uk.
Cancer Immunotherapy, also known as immuno-oncology, is a form
of cancer treatment that uses the power of the body's own immune
system to prevent, control, and eliminate cancer. Cancer
Immunotherapy can:
-- Educate the immune system to recognise and attack specific cancer cells;
-- Boost immune cells to help them eliminate cancer; and
-- Provide the body with additional components to enhance the immune response.
Unleashing the power of the immune system is considered to be a
smart way to fight cancer because:
-- The immune system is precise, so it is possible for it to
target cancer cells exclusively while
sparing healthy cells;
-- The immune system can adapt continuously and dynamically,
just like cancer does, so if a tumour
manages to escape detection, the immune system can re-evaluate
and launch a new attack; and
-- The immune system's "memory" allows it to remember what
cancer cells look like, so it can target
and eliminate the cancer if it returns.
(Source: The Cancer Research Institute,
www.cancerresearch.org)
- Ends -
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RESLLFLDIRLAFIA
(END) Dow Jones Newswires
October 30, 2019 03:00 ET (07:00 GMT)
Grafico Azioni Sareum (LSE:SAR)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Sareum (LSE:SAR)
Storico
Da Apr 2023 a Apr 2024